Global medical technology company, Zimmer Biomet, has reported second-quarter 2026 revenues of approximately $2.18 billion, marking a 4.8% year-on-year (YoY) increase, while raising its full-year revenue growth and earnings guidance following a strong first-half performance.

The company's knees business remained its largest revenue contributor, generating $828.9 million during the quarter, followed by the Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic (S.E.T.) segment at $586 million and the hips business at $562.7 million.

Although the technology and data, bone cement and surgical segment recorded the lowest quarterly revenue at $199.4 million, it delivered the strongest growth, rising 21.1% YoY. The S.E.T. business grew 6.4%, while hips increased 5%. Revenue from the knees segment was largely stable, posting 0.4% YoY growth.

Based on its first-half performance, Zimmer Biomet has revised its FY2026 revenue growth forecast to 3.9%–4.9%, compared with its earlier guidance of 2.5%–4.5%. The company also increased its adjusted earnings guidance to $8.47–$8.59 per diluted share, up from the previous range of $8.40–$8.55.

The results were announced ahead of the market opening on August 5. Following the announcement, Zimmer Biomet's shares rose more than 5% on the New York Stock Exchange (NYSE) to around $101, compared with the previous close of $95.81. The company currently has a market capitalization of approximately $19.63 billion.

Commenting on the results, Ivan Tornos, Chairman, President and CEO of Zimmer Biomet, said the company had delivered a strong first half supported by healthy market conditions, progress in its go-to-market strategy, and continued momentum from its innovation pipeline.

“With a strong first half, healthy underlying markets, go-to-market changes progressing as planned and continued momentum from our innovation cycle, we are raising our revenue and adjusted earnings per share (EPS) guidance for the year,” Tornos said.